Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.37 -1.8%	$0.39	$0.30 ▼ $10.62	$51.68M	1.86	3.38 million shs	850,308 shs
IPSC Century Therapeutics	$0.60 -1.0%	$0.53	$0.34 ▼ $3.32	$51.70M	1.77	521,579 shs	399,566 shs
NVLNF Novelion Therapeutics	$0.70 -1.2%	$0.70	$0.51 ▼ $1.00	$13.77M	2.15	261,364 shs	26,900 shs
QNCX Quince Therapeutics	$1.20 -4.0%	$1.06	$0.51 ▼ $2.45	$54.56M	0.8	294,007 shs	1.22 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	-3.70%	-0.96%	-19.63%	-25.60%	-92.67%
IPSC Century Therapeutics	-4.52%	+6.90%	+15.51%	+8.52%	-81.35%
NVLNF Novelion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
QNCX Quince Therapeutics	+4.17%	+14.68%	+21.36%	-11.35%	+58.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.2842 of 5 stars	3.3	3.0	0.0	4.7	3.3	1.7	0.6
IPSC Century Therapeutics	2.5404 of 5 stars	3.5	4.0	0.0	0.0	1.0	1.7	0.6
NVLNF Novelion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	3.6977 of 5 stars	3.6	5.0	0.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,571.23% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	600.00% Upside
NVLNF Novelion Therapeutics	0.00	N/A	N/A	N/A
QNCX Quince Therapeutics	3.29	Buy	$8.00	566.67% Upside

Current Analyst Ratings Breakdown

Latest NVLNF, QNCX, IPSC, and APLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/14/2025	APLT Applied Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $4.00
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/24/2025	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	IPSC Century Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.00 ➝ $2.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$265K	195.00	N/A	N/A	($0.20) per share	-1.83
IPSC Century Therapeutics	$114.90M	0.45	N/A	N/A	$3.06 per share	0.20
NVLNF Novelion Therapeutics	$130.43M	0.11	N/A	N/A	($4.69) per share	-0.15
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$1.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$119.76M	-$0.43	N/A	N/A	N/A	N/A	-260.75%	-76.04%	8/6/2025 (Estimated)
IPSC Century Therapeutics	-$136.67M	-$0.29	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	8/14/2025 (Estimated)
NVLNF Novelion Therapeutics	-$108.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	-$31.39M	-$1.39	N/A	N/A	N/A	N/A	-53.27%	-22.73%	8/12/2025 (Estimated)

Latest NVLNF, QNCX, IPSC, and APLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
4/14/2025	Q4 2024	APLT Applied Therapeutics	-$0.18	-$0.24	-$0.06	$0.33	$0.61 million	$0.00 million
3/24/2025	Q4 2024	QNCX Quince Therapeutics	-$0.19	-$0.28	-$0.09	-$0.28	N/A	$0.17 million
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
NVLNF Novelion Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	1.06	1.06
IPSC Century Therapeutics	N/A	10.39	10.39
NVLNF Novelion Therapeutics	N/A	N/A	N/A
QNCX Quince Therapeutics	0.33	9.53	9.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
IPSC Century Therapeutics	50.20%
NVLNF Novelion Therapeutics	48.64%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
IPSC Century Therapeutics	6.80%
NVLNF Novelion Therapeutics	3.60%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	106.35 million	Optionable
IPSC Century Therapeutics	170	86.16 million	79.25 million	Optionable
NVLNF Novelion Therapeutics	109	19.62 million	N/A	Not Optionable
QNCX Quince Therapeutics	60	45.47 million	36.61 million	Optionable

NVLNF, QNCX, IPSC, and APLT Headlines

Recent News About These Companies

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12 at 5:15 PM | businesswire.com

Quince Therapeutics' (QNCX) Buy Rating Reiterated at D. Boral Capital

June 6, 2025 | americanbankingnews.com

Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $8.00

June 4, 2025 | americanbankingnews.com

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 3, 2025 | businesswire.com

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025 | seekingalpha.com

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | finance.yahoo.com

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025 | businesswire.com

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

January 24, 2025 | finance.yahoo.com

Quince Therapeutics initiated with a Buy at Brookline

December 19, 2024 | msn.com

Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation

December 19, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVLNF, QNCX, IPSC, and APLT Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.36 -0.01 (-1.83%)

As of 04:00 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Century Therapeutics NASDAQ:IPSC

$0.60 -0.01 (-1.01%)

As of 04:00 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Novelion Therapeutics OTCMKTS:NVLNF

$0.70 -0.01 (-1.20%)

As of 01/16/2020

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Quince Therapeutics NASDAQ:QNCX

$1.20 -0.05 (-4.00%)

As of 04:00 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time